Menu
Home
TMU
Sitemap
FAQ
Links
Online Portals
TMU Online Resources
External Online Resources
Affiliated Hospitals
REACTA
TCTI 2025
正體中文
Search
News
News
Announcements
Government
Events
Business
Charges
About OHR
About OHR
OHR Overview
Dean
OHR Members
Department
JIRB Administration Section
Data Safety Managing Section
Joint Clinical Research Center
Joint Biobank
Business
Business
Clinical Trial
Clinical Trial Agreement
Investigator-Initiated Trial
Project Writing Consultation
Ongoing Clinical Trials
Biobank
Biobank Application
Number of Specimen and Omic Data
Participant Rights and Complaint Procedures
TMU-JIRB
TMU-JIRB
About TMU-JIRB
Introduction
Administrative Staff
Members
SOP
Application Forms
IRB Submission
Charges
Meeting Date
Meeting Minutes
FAQs
Download
Download
Form
Clinical Trial
Regulation
TMU Regulation
Domestic Regulation
Related Regulation
System
ATM system
Contact
Contact
Contact Info
Website Feedback Form
Home
Ongoing Clinical Trials
Ongoing Clinical Trials
Institution
All
SHH
TMUH
WFH
Principal Investigator
All
Chao-Hua Chiu
Chaur-Jong Hu
Che-Hsuan Lin
Chen-Chih Chung
Chen-Yuan Chiang
Chi-Ching Chang
Chi-Hao Hsiao
Chia-Lun Chang
Chia-Yu Wu
Chien-Hua Tseng
Chien-Tai Hong
Chien-Yi Hsu
Chih-Hao Yang
Chih-Horng Wu
Chih-hsin Lee
Chih-Hwa Chen
Chih-Wei Chen
Chih-Yuan Fang
Chin-Sheng Hung
Ching-Fu Wang
Ching-Jung Lin
Ching-Shan Luo
Chun-Chao Chen
Chun-liang Chou
Chun-Yao Huang
Chung-Yi Cheng
Chung-Ze Wu
Ciat-Wuah Khoo
Han-Chuan Chuang
Han-Lin Hsu
Han-Pin Kuo
Hsi-Hsien Chen
Hsin-Chieh Lee
Hsin-Chien Lee
Hsin-Yi Chiu
Hui-Ching Hsu
Hung-Cheng Lai
Hung-Chou Chen
Hung-Yen Chin
I-Wen Wu
J. Timothy Qiu
Jen-Her Lu
Jer-Hwa Chang
Jinn-Li Wang
Jiunn-Horng Kang
Jong Shiuan Yeh
Jowy Tani
Ju-Chi Liu
Kai-Ling Lee
Kai-Yi Tzou
Kang-Yun Lee
Kuan-Chou Chen
Kuan-Chou Lin
Kuan-Chun Kao
Kuo-Hsuan Chung
Li-Sheng Chen
Lung Chan
Mai-Szu Wu
Mei-Yi Wu
Ming-Che Liu
Ming-Chin Lin
Ming-Hsiu Lin
Ming-Shun Wu
Ming-Yao Chen
Nai-Chia Teng
Pai-Chien Chou
Po-Hao Feng
Po-Li Wei
Po-Yueh Chen
Rong-Hong Hsieh
Shauh-Der Yeh
Sheng-Hong Lin
Shih-Chung Lai
Shih-Hsin Hsiao
Shou-Cheng Lu
Shu-Huey Chen
Shu-Ping Chao
Shun-Cheng Chang
Szu-Wei Huang
Ting-Yun Huang
Tsong Yih Ou
Tsu-Yi Chao
Tsung-Lin Yang
Tung-Nien Hsu
Tung-Yao Tsai
Tze-Sian Chan
Tze-Wah Kao
Tzeon-Jye Chiou
Tzu-I Wu
Tzu-Min Lin
Tzu-Yao Liao
Tzu-Yu Weng
Wei-Hong Cheng
Wei-Jen Chang
Wei-Ta Chen
Wei-Yu Kao
Wen-Kuan Chiu
Wen-Rui Hao
Wen-Sen Lee
Woan-Ruoh Lee
Ya-Wen Hsiao
Yang-Jen Chiang
Yao-Yu Hsieh
Yen-Chen Wu
Yen-Lin Liu
Yen-Wen Huang
Yen-Ying Chen
Yi-Hsien Lin
Yi-Hsien Shih
Yu-Sheng Chang
Yueh-Hsun Lu
Yung-Ho Hsu
Yung-Kuo Lin
Yung-Ting Kuo
Yung-Wei Lin
Protocol Title
Keyword
Search
Clear
TMU-JIRB No.
Protocol Title
Institution / Principal Investigator
Type of Study
Phases of Clinical Trials for Drugs
N202609049
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
TMUH /
Hsin-Chien Lee
New Drug
Phase Ⅲ
N202609085
An open-label, single-dose study to characterize the pharmacokinetics and safety of NH002 in healthy volunteers and participants with compromised pulmonary conditions
TMUH /
Pai-Chien Chou
New Drug
Phase Ⅰ
N202609086
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
TMUH /
Shih-Hsin Hsiao
New Drug
Phase Ⅲ
N202610001
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of secutrelvir in participants with COVID-19
WFH /
Tsong Yih Ou
New Drug
Phase Ⅲ
N202610012
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
TMUH /
Chao-Hua Chiu
New Drug
Phase Ⅲ
N202610014
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]
SHH /
Yung-Ho Hsu
New Drug
Phase Ⅲ
N202610024
A randomized, open-label (unblinding), four-period, fully replicated, crossover bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state.
SHH /
Chun-Chao Chen
Bioavailability / Bioequivalence (BA/BE)
NA
N202610025
A preliminary bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state.
SHH /
Chun-Chao Chen
Bioavailability / Bioequivalence (BA/BE)
NA
N202610037
An Open-Label, Randomized, and Crossover Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Film-Coated Tablets in Healthy Subjects under Fasting Conditions
WFH /
Jer-Hwa Chang
Bioavailability / Bioequivalence (BA/BE)
NA
N202610045
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)
TMUH /
Chao-Hua Chiu
New Drug
Phase Ⅲ
1
2
25
26
27
28
29
30
31
32
33
34
/
34
TOP